Urologic Complications of Friedreich’s Ataxia

  • Elizabeth V. Dray


Friedrich’s ataxia is an early onset hereditary condition that causes progressive neurologic decline. Common urologic symptoms include urinary frequency, urgency, and incontinence. Elevated post-void residuals are also not uncommon. Urodynamic testing may demonstrate detrusor overactivity and detrusor sphincter dyssynergia but usually the bladder compliance is normal. Urologic treatment goals revolve around emptying the bladder completely via intermittent catheterization or indwelling catheter and managing overactive bladder symptoms with medications or onabotulinum injections. Friedrich’s ataxia patients have a potentially high risk of surgical complications due to underlying respiratory weakness and cardiac pathologies.


Friedreich’s ataxia Urinary incontinence Urinary frequency Urodynamics Treatment 


  1. 1.
    Vankan P. Prevalence gradients of Friedreich’s ataxia and R1b haplotype in Europe co-localize, suggesting a common Palaeolithic origin in the Franco-Cantabrian ice age refuge. J Neurochem. 2013;126(Suppl):11–20.CrossRefGoogle Scholar
  2. 2.
    Parkinson MH, Boesch S, Nachbauer W, Mariotti C, Giunti P. Clinical features of Friedreich’s ataxia: classical and atypical phenotypes. J Neurochem. 2013;126:103–17.CrossRefGoogle Scholar
  3. 3.
    Campuzano V, et al. Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271:1423–7.CrossRefGoogle Scholar
  4. 4.
    Dürr A, et al. Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med. 1996;335:1169–75.CrossRefGoogle Scholar
  5. 5.
    Cossée M, et al. Friedreich’s ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol. 1999;45:200–6.CrossRefGoogle Scholar
  6. 6.
    Evans-Galea MV, et al. FXN methylation predicts expression and clinical outcome in Friedreich ataxia. Ann Neurol. 2012;71:487–97.CrossRefGoogle Scholar
  7. 7.
    Branda SS, Yang ZY, Chew A, Isaya G. Mitochondrial intermediate peptidase and the yeast frataxin homolog together maintain mitochondrial iron homeostasis in Saccharomyces cerevisiae. Hum Mol Genet. 1999;8:1099–110.CrossRefGoogle Scholar
  8. 8.
    Cnop M, Mulder H, Igoillo-Esteve M. Diabetes in Friedreich ataxia. J Neurochem. 2013;126(Suppl):94–102.CrossRefGoogle Scholar
  9. 9.
    Regner SR, et al. Analysis of echocardiograms in a large heterogeneous cohort of patients with friedreich ataxia. Am J Cardiol. 2012;109:401–5.CrossRefGoogle Scholar
  10. 10.
    Tsou AY, et al. Mortality in Friedreich ataxia. J Neurol Sci. 2011;307:46–9.CrossRefGoogle Scholar
  11. 11.
    Cook A, Giunti P. Friedreich’s ataxia: clinical features, pathogenesis and management. Br Med Bull. 2017;124:19–30.CrossRefGoogle Scholar
  12. 12.
    Reetz K, et al. Biological and clinical characteristics of the European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurol. 2015;14:174–82.CrossRefGoogle Scholar
  13. 13.
    Dogan I, et al. Structural characteristics of the central nervous system in Friedreich ataxia: an in vivo spinal cord and brain MRI study. J Neurol Neurosurg Psychiatry. 2018;1(3) Scholar
  14. 14.
    Corben LA, Lynch D, Pandolfo M, Schulz JB, Delatycki MB. Consensus clinical management guidelines for Friedreich ataxia. Orphanet J Rare Dis. 2014;9:1–12.CrossRefGoogle Scholar
  15. 15.
    Vezina JG, Bouchard JP, Bouchard R. Urodynamic evaluation of patients with hereditary ataxias. Can J Neurol Sci. 1982;9:127–9.CrossRefGoogle Scholar
  16. 16.
    Diez Rodríguez JM, et al. Clinico-urodynamic correlation in the hereditary ataxias. Arch Esp Urol. 2003;56:915–25.PubMedGoogle Scholar
  17. 17.
    Musegante AFA, Almeida PNS, Monteiro RTM, Barroso U. Urinary symptoms and urodynamics findings in patients with Friedreich’s Ataxia. Int Braz J Urol. 2013;39:867–74.CrossRefGoogle Scholar
  18. 18.
    Lad M, et al. Urinary, bowel and sexual symptoms in a cohort of patients with Friedreich’s ataxia. Orphanet J Rare Dis. 2017;12:1–6.CrossRefGoogle Scholar
  19. 19.
    Stoffel JT, et al. AUA white paper on nonneurogenic chronic urinary retention: consensus definition, treatment algorithm, and outcome end points. J Urol. 2017;198:153–60.CrossRefGoogle Scholar
  20. 20.
    Dray E, et al. Does post-void residual volume predict worsening urological symptoms in patients with multiple sclerosis? J Urol. 2018;200:868–74.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Elizabeth V. Dray
    • 1
  1. 1.Division of Urology, Department of SurgeryGreenville Health SystemGreenvilleUSA

Personalised recommendations